2. Search Result
Search Result
Pathways Recommended: PI3K/Akt/mTOR
Results for "

Akt activity

" in MedChemExpress (MCE) Product Catalog:

286

Inhibitors & Agonists

6

Screening Libraries

2

Biochemical Assay Reagents

6

Peptides

1

Inhibitory Antibodies

116

Natural
Products

5

Isotope-Labeled Compounds

3

Click Chemistry

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0797
    (20S)-Protopanaxadiol

    20-Epiprotopanaxadiol; 20(S)-APPD

    		 P-glycoprotein Reactive Oxygen Species Apoptosis Cancer
    20S-protopanaxadiol (aPPD) is a metabolite of ginseng saponins, inhibits Akt activity and induces apoptosis in various tumor cells .
    (20S)-Protopanaxadiol
  • HY-19542
    C6 Ceramide
    2 Publications Verification

    C6-Cer; N-Hexanoylsphingosine

    		 Apoptosis Cancer
    C6 Ceramide (C6-Cer) is a short-chain, cell-permeable ceramide pathway activator with anticancer activity. C6 Ceramide-mediated miR-29b expression participates in the progression of multiple myeloma through suppressing the proliferation, migration and angiogenesis of endothelial cells by targeting Akt signal pathway. C6 Ceramide exhibits multiple anti-cancer properties including cell cycle arrest, Apoptosis, inhibition of tumor growth and enhances the effects of chemotherapy in drug-resistant cancer cells. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects .
    C6 Ceramide
  • HY-100018
    BAY1125976
    1 Publications Verification

    		 Akt Cancer
    BAY1125976 is a selective allosteric Akt1/Akt2 inhibitor; inhibits Akt1 and Akt2 activity with IC50 values of 5.2 nM and 18 nM at 10 μM ATP, respectively.
    BAY1125976
  • HY-129119
    Akt1/Akt2-IN-2

    		Akt Caspase Cancer
    Akt1/Akt2-IN-2 (compound 7) is an allosteric dual Akt1 and Akt2 inhibitor (IC50=138 nM and 212 nM, respectively). Akt1/Akt2-IN-2 increases activity of caspase-3, and inhibits viability of a number of tumor cells .
    Akt1/Akt2-IN-2
  • HY-50862
    Akt1/Akt2-IN-1
    1 Publications Verification

    		 Akt Cancer
    Akt1/Akt2-IN-1 (Compound 17) is an allosteric inhibitor of Akt1 (IC50=3.5 nM) and Akt2 (IC50=42 nM), with potent and balanced activity .
    Akt1/Akt2-IN-1
  • HY-10249A
    AKT Kinase Inhibitor
    10+ Cited Publications

    		 Akt Cancer
    AKT Kinase Inhibitor is an Akt kinase inhibitor with anti-tumor activity .
    AKT Kinase Inhibitor
  • HY-10355
    AKT inhibitor VIII
    45+ Cited Publications

    Akti-1/2

    		 Akt Apoptosis Metabolic Disease Cancer
    AKT inhibitor VIII (AKTi-1/2) is a cell-permeable quinoxaline compound that has been shown to potently, selectively, allosterically, and reversibly inhibit Akt1, Akt2, and Akt3 activity with IC50s of 58 nM, 210 nM, and 2119 nM, respectively.
    AKT inhibitor VIII
  • HY-N0797R
    (20S)-Protopanaxadiol (Standard)

    		P-glycoprotein Reactive Oxygen Species Apoptosis Cancer
    (20S)-Protopanaxadiol (Standard) is the analytical standard of (20S)-Protopanaxadiol. This product is intended for research and analytical applications. 20S-protopanaxadiol (aPPD) is a metabolite of ginseng saponins, inhibits Akt activity and induces apoptosis in various tumor cells .
    (20S)-Protopanaxadiol (Standard)
  • HY-13661
    7-Hydroxystaurosporine

    UCN-01; KRX-0601

    		 Akt PKC CDK Apoptosis Cancer
    7-Hydroxystaurosporine (UCN-01) is a synthetic derivative of Staurosporine (HY-15141) with antitumor activity. 7-hydroxystaurosporine inhibits serine/threonine kinase AKT and calcium-dependent protein kinase C activity. 7-hydroxystaurosporine also activates indirectly cyclin-dependent kinases (CDKs). 7-hydroxystaurosporine arrests tumor cells in the G1/S of the cell cycle and prevents nucleotide excision repair by inhibiting the G2 checkpoint kinase chk1, resulting in apoptosis .
    7-Hydroxystaurosporine
  • HY-156796
    Akt/ROCK-IN-1

    		ADC Cytotoxin Neurological Disease Cancer
    Akt/ROCK-IN-1 (B12) is a dual inhibitor for Akt and ROCK, with the IC50s of 0.023 nM and 1.47 nM, respectively. Akt/ROCK-IN-1 has antitumor activity for neuroblastoma .
    Akt/ROCK-IN-1
  • HY-161144
    AKT-IN-21

    		Akt Apoptosis Cancer
    AKT-IN-21 (compound C36) is a potent AKT inhibitor with broad-spectrum cytotoxicity and anticancer activity. AKT-IN-21 also blocks the cell cycle and induces apoptosis of cancer cells by down-regulating the PI3K/AKT pathway .
    AKT-IN-21
  • HY-147836
    Akt/NF-κB/JNK-IN-1

    		Akt NF-κB JNK TNF Receptor COX Inflammation/Immunology
    Akt/NF-κB/JNK-IN-1 (Compound 2i) is an inhibitor of Akt, NF-κB and JNK signaling pathways. Akt/NF-κB/JNK-IN-1 inhibits nitric oxide production with an IC50 of 3.15 μM. Akt/NF-κB/JNK-IN-1 shows anti-inflammatory activities .
    Akt/NF-κB/JNK-IN-1
  • HY-126257
    AKT-IN-3

    		Akt Apoptosis Cancer
    AKT-IN-3 (compound E22) is a potent, orally active low hERG blocking Akt inhibitor, with 1.4 nM, 1.2 nM and 1.7 nM for Akt1, Akt2 and Akt3, respectively. AKT-IN-3 (compound E22) also exhibits good inhibitory activity against other AGC family kinases, such as PKA, PKC, ROCK1, RSK1, P70S6K, and SGK. AKT-IN-3 (compound E22) induces apoptosis and inhibits metastasis of cancer cells .
    AKT-IN-3
  • HY-10249D
    AKT Kinase Inhibitor hydrochloride
    10+ Cited Publications

    		 Akt Cancer
    AKT Kinase Inhibitor hydrochloride is an Akt kinase inhibitor with anti-tumor activity . AKT Kinase Inhibitor (hydrochloride) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    AKT Kinase Inhibitor hydrochloride
  • HY-151613
    MS15

    		PROTACs Akt Cancer
    MS15 is a potent and selective AKT PROTAC degrader. MS15 inhibits the AKT1, -2, and -3 activities, with IC50 values of 798 nM, 90 nM, and 544 nM, respectively .
    MS15
  • HY-161861
    VEGFR-2/AKT-IN-1

    		VEGFR Akt Cancer
    VEGFR-2/AKT-IN-1 (compound 17) is a dual inhibitor of VEGFR-2 and AKT, with the IC50s of 0.164 μM and 0.452 μM, respectively. VEGFR-2/AKT-IN-1 has antitumor activity .
    VEGFR-2/AKT-IN-1
  • HY-151613A
    MS15 TFA

    		PROTACs Akt Cancer
    MS15 TFA is a potent and selective AKT PROTAC degrader. MS15 TFA inhibits the AKT1, -2, and -3 activities, with IC50 values of 798 nM, 90 nM, and 544 nM, respectively .
    MS15 TFA
  • HY-10249
    GSK-690693
    30+ Cited Publications

    		 Akt AMPK Autophagy Cancer
    GSK-690693 is an ATP-competitive pan-Akt inhibitor with IC50s of 2 nM, 13 nM, 9 nM for Akt1, Akt2 and Akt3, respectively. GSK-690693 is also an AMPK inhibitor, affects Unc-51-like autophagy activating kinase 1 (ULK1) activity and robustly inhibits STING-dependent IRF3 activation .
    GSK-690693
  • HY-108232
    MK-2206
    Maximum Cited Publications
    359 Publications Verification

    		 Organoid Akt Autophagy Apoptosis Cancer
    MK-2206 is an orally active, highly potent and selective allosteric Akt inhibitor, with IC50s of 8, 12, and 65 nM for Akt1, Akt2, and Akt3, respectively. Many breast cancer cell lines, and PIK3CA-mutant and cell lines with PTEN loss are sensitive to MK-2206. MK-2206 has anticancer activities .
    MK-2206
  • HY-151606
    Akt3 degrader 1

    		Akt Cancer
    Akt3 degrader 1 (compound 12l) is a selective Akt3 degrader that overcomes Osimertinib (HY-15772)-induced resistance in H1975OR NSCLC cells. Akt3 degrader 1 also has anti-proliferative activity and significantly inhibits tumour growth in mice. Akt3 degrader 1 can be used in the study of drug-resistant non-small cell lung cancer .
    Akt3 degrader 1
  • HY-149496
    Akt/NF-κB/MAPK-IN-1

    		p38 MAPK ERK JNK Interleukin Related TNF Receptor NO Synthase COX Others
    Akt/NF-κB/MAPK-IN-1 (compound 2m) is a potent and orally active inhibitor against NO (IC50=7.70 μM) with no significant toxicity. Akt/NF-κB/MAPK-IN-1 shows anti-inflammatory activity by inhibiting Akt/NF-κB and MAPK signaling pathways .
    Akt/NF-κB/MAPK-IN-1
  • HY-144806
    PI3K/AKT-IN-1
    5+ Cited Publications

    		 PI3K Akt Apoptosis Cancer
    PI3K/AKT-IN-1 is an effective PI3K/AKT dual inhibitor (IC50 of 6.99, 4.01 and 3.36 μM for PI3Kγ, PI3Kδ and AKT, respectively). PI3K/AKT-IN-1 has anticancer activity and acts by inhibiting PI3K/AKT axis and inducing caspase 3 dependent apoptosis .
    PI3K/AKT-IN-1
  • HY-100501
    M2698

    MSC2363318A

    		 Ribosomal S6 Kinase (RSK) Akt Cancer
    M2698 (MSC2363318A) is an orally active, ATP competitive, selective p70S6K and Akt dual-inhibitor with IC50s of 1 nM for p70S6K, Akt1 and Akt3. M2698 can cross the blood-brain barrier and has anti-cancer activity .
    M2698
  • HY-13260
    CCT128930
    5 Publications Verification

    		 Akt Autophagy Apoptosis Cancer
    CCT128930 is a ATP-competitive and selective inhibitor of AKT (IC50=6 nM for AKT2). CCT128930 has 28-fold selectivity over the closely related PKA kinase (IC50=168 nM) through the targeting of Met282 of AKT (Met173 of PKA-AKT chimera), as well as 20-fold selectivity over p70S6K (IC50=120 nM). Antitumor activity.
    CCT128930
  • HY-10357
    MK-2206 free base

    		Organoid Akt Autophagy Apoptosis Cancer
    MK-2206 free base is an orally active, highly potent and selective allosteric Akt inhibitor, with IC50s of 8, 12, and 65 nM for Akt1, Akt2, and Akt3, respectively. Many breast cancer cell lines, and PIK3CA-mutant and cell lines with PTEN loss are sensitive to MK-2206 free base. MK-2206 free base has anticancer activities .
    MK-2206 free base
  • HY-161857
    Akt/mTOR-IN-1

    		Akt mTOR Caspase CDK Cancer
    Akt/mTOR-IN-1 (Compound 8r) is an AKT/mTOR signaling pathway inhibitor exhibiting an IC50 value of 0.8 µM with anticancer activity. Akt/mTOR-IN-1 can decrease the expression of Caspase 3 and increase the expression of the autophagic protein Cyclin B1, thereby inducing cell autophagy and apoptosis. Akt/mTOR-IN-1 can be used in research related to non-small cell lung cancer (NSCLC) .
    Akt/mTOR-IN-1
  • HY-18933
    BI-69A11

    		Akt Cancer
    BI-69A11 is an AKT inhibitor that can effectively suppress the phosphorylation of AKT. BI-69A11 exhibits anticancer activity and can lead to the death of melanoma cells and prostate tumor cells .
    BI-69A11
  • HY-N1505
    Loureirin A
    5 Publications Verification

    		 Akt Cardiovascular Disease
    Loureirin A is a flavonoid extracted from Dragon's Blood, can inhibit Akt phosphorylation, and has antiplatelet activity.
    Loureirin A
  • HY-160469
    INY-05-040

    		Akt PROTACs Cancer
    INY-05-040 is a AKT degrader that can selectively and quickly degrade all three AKT isoforms. INY-05-040 can inhibit downstream signaling and cell proliferation in 288 cancer cell lines, with anti-cancer activity .
    INY-05-040
  • HY-101625
    Recilisib
    20+ Cited Publications

    ON 01210

    		 Akt PI3K Cancer
    Recilisib (ON 01210) is a radioprotectant, which can activate AKT, PI3K activities in cells .
    Recilisib
  • HY-101625A
    Recilisib sodium

    ON 01210 sodium

    		 Akt PI3K Cancer
    Recilisib sodium (ON 01210) is a radioprotectant, which can activate AKT, PI3K activities in cells .
    Recilisib sodium
  • HY-161351
    STAT3/AKT-IN-1

    		Akt STAT Apoptosis Cancer
    STAT3/AKT-IN-1 is a dual inhibitor for the signal transducer and activator of transcription 3 (STAT3) and protein kinase B (AKT) signalling pathway, exhibits antitumor activity against gastric cancer and induces cell apoptosis in SGC-7901 cells .
    STAT3/AKT-IN-1
  • HY-147913
    PI3K/Akt/mTOR-IN-3

    		PI3K Akt mTOR Apoptosis Cancer
    PI3K/Akt/mTOR-IN-3 (compound 3d) is a potent PI3K/AKT/mTOR inhibitor. PI3K/Akt/mTOR-IN-3 displays the inhibitory activity in MCF-7, HeLa and HepG2 cells, with IC50 values of 0.77, 1.23, and 4.57μM, respectively. PI3K/Akt/mTOR-IN-3 inhibits the migration of MCF-7 and HeLa cells at the concentration of 4 μM. PI3K/Akt/mTOR-IN-3 induces cell apoptosis and S phase arrest .
    PI3K/Akt/mTOR-IN-3
  • HY-N2283
    Deltonin
    1 Publications Verification

    		 ERK Akt Endogenous Metabolite Cancer
    Deltonin, a steroidal saponin, isolated from Dioscorea zingiberensis, has antitumor activity; Deltonin inhibits ERK1/2 and AKT activation.
    Deltonin
  • HY-19934A
    Pifusertib hydrochloride

    TAS-117 hydrochloride

    		 Akt Apoptosis Autophagy Cancer
    Pifusertib (TAS-117) hydrochloride is a potent, selective, orally active allosteric Akt inhibitor (with IC50s of 4.8, 1.6, and 44 nM for Akt1, 2, and 3, respectively). Pifusertib hydrochloride triggers anti-myeloma activities and enhances fatal endoplasmic reticulum (ER) stress induced by proteasome inhibition. Pifusertib hydrochloride induces apoptosis and autophagy .
    Pifusertib hydrochloride
  • HY-19934
    Pifusertib

    TAS-117

    		 Akt Apoptosis Autophagy Cancer
    Pifusertib (TAS-117) is a potent, selective, orally active allosteric Akt inhibitor (with IC50s of 4.8, 1.6, and 44 nM for Akt1, 2, and 3, respectively). Pifusertib triggers anti-myeloma activities and enhances fatal endoplasmic reticulum (ER) stress induced by proteasome inhibition. Pifusertib induces apoptosis and autophagy .
    Pifusertib
  • HY-13260A
    CCT128930 hydrochloride
    5 Publications Verification

    		 Akt Autophagy Apoptosis Cancer
    CCT128930 hydrochloride is a potent and selective inhibitor of AKT (IC50=6 nM). CCT128930 hydrochloride has 28-fold selectivity over the closely related PKA kinase (IC50=168 nM) through the targeting of Met282 of AKT (Met173 of PKA-AKT chimera), as well as 20-fold selectivity over p70S6K (IC50=120 nM). CCT128930 hydrochloride induces cell cycle arrest, DNA damage, and autophagy. Antitumor activity .
    CCT128930 hydrochloride
  • HY-117885
    PF-5177624

    		PDK-1 Cancer
    PF-5177624 is a specific and potent inhibitor of PDK1, a key enzyme in the PI3K/AKT signaling pathway that is frequently dysregulated in breast cancer. PDK1 phosphorylates AKT at T308 and other substrates, activating downstream signaling pathways that are important for tumor progression. PF-5177624 blocks IGF-1-stimulated PDK1 activity and downstream AKT and p70S6K phosphorylation, reducing cell proliferation and transformation in breast cancer cells .
    PF-5177624
  • HY-159517
    PI3K/Akt/mTOR-IN-5

    		Apoptosis PI3K Akt mTOR STAT Cancer
    PI3K/Akt/mTOR-IN-5 (compound D3) is a derivative of Pseudolaric Acid B (HY-N6939) with anti-tumor activity. PI3K/Akt/mTOR-IN-5 inhibits excessive proliferation of tumor cells through the PI3K/AKT/mTOR and STAT3/GPX4 pathways. PI3K/Akt/mTOR-IN-5 effectively inhibits EDU positivity, reduces colony formation, places HCT-116 cells in the S phase and G2/M phase, and induces apoptosis .
    PI3K/Akt/mTOR-IN-5
  • HY-N1904
    4′-Hydroxywogonin

    8-Methoxyapigenin

    		 IKK NF-κB p38 MAPK PI3K Akt Reactive Oxygen Species Interleukin Related TNF Receptor Apoptosis Caspase Bcl-2 Family Cardiovascular Disease Inflammation/Immunology Cancer
    4′-Hydroxywogonin (8-Methoxyapigenin), a flavonoid, could be isolated from a variety of plants including Scutellaria barbata and Verbena littoralis. 4′-Hydroxywogonin has anti-inflammatory activity via TAK1/IKK/NF-κB, MAPKs and PI3/AKT signaling pathways. 4′-Hydroxywogonin inhibits angiogenesis by disrupting PI3K/AKT signaling. 4′-Hydroxywogonin inhibits cell proliferation and induces apoptosis .
    4′-Hydroxywogonin
  • HY-106263B
    Tyroserleutide hydrochloride

    		PTEN PDK-1 MDM-2/p53 Apoptosis Akt Cancer
    Tyroserleutide hydrochloride is a tripeptide isolated from the degradation products of porcine spleen with antitumor activity. Tyroserleutide hydrochloride can upregulate the expression of the tumor suppressor gene PTEN and inhibit the activity of AKT and PDK1. Tyroserleutide hydrochloride inhibits tumor cell proliferation and MDM2 phosphorylation by inhibiting the PI3K/AKT pathway, and also upregulates P21, P27, P53, and induces mitochondrial damage and cell apoptosis .
    Tyroserleutide hydrochloride
  • HY-N4182
    Licochalcone E

    		Akt p38 MAPK Autophagy Inflammation/Immunology
    Licochalcone E, a flavonoid compound isolated from Glycyrrhiza uralensis, inhibits NF-κB and AP-1 transcriptional activity through the inhibition of AKT and MAPK activation .
    Licochalcone E
  • HY-122965
    Batatasin III

    		FAK Akt Cancer
    Batatasin III, a stilbenoid, inhibits cancer migration and invasion by suppressing epithelial to mesenchymal transition (EMT) and FAK-AKT signals. Batatasin III has anti-cancer activities .
    Batatasin III
  • HY-127067
    Yuanhuadin

    		Akt EGFR mTOR Inflammation/Immunology Cancer
    Yuanhuadin, extracted from Genkwa Flos Daphne genkwa, has antitumor activity through inhibiting Akt/mTOR and EGFR pathways, induce cell-cycle arrest and abortion .
    Yuanhuadin
  • HY-169407
    AKT-IN-24

    		Akt mTOR MEK ERK Apoptosis Cancer
    KT-IN-24 (Compound M17) is a AKT allosteric inhibitor with anti-tumor activity. KT-IN-24 can target the AKT/mTOR and MEK/ERK signaling pathways and inhibit epithelial-mesenchymal transition, which has a synergistic suppressive effect on TNBC, promoting cell apoptosis while inhibiting proliferation and migration when used in combination with Trametinib (HY-10999) .
    AKT-IN-24
  • HY-142019
    Tanshinol borneol ester

    		Akt AMPK Cardiovascular Disease
    Tanshinol borneol ester, an angiogenesis stimulator, promoted multiple key steps of angiogenesis through Akt and MAPK signalling pathways. Tanshinol borneol ester has anti-ischemic and anti-atherosclerosis activities .
    Tanshinol borneol ester
  • HY-N1505R
    Loureirin A (Standard)

    		Akt Cardiovascular Disease
    Loureirin A (Standard) is the analytical standard of Loureirin A. This product is intended for research and analytical applications. Loureirin A is a flavonoid extracted from Dragon's Blood, can inhibit Akt phosphorylation, and has antiplatelet activity.
    Loureirin A (Standard)
  • HY-162802
    PI3K/AKT-IN-4

    		Apoptosis PI3K Akt PARP CDK Cancer
    PI3K/AKT-IN-4 (compound 3) is a diterpenoid that can be isolated from the roots and rhizomes of Salvia castanea Dielsf. PI3K/AKT-IN-4 has antitumor activity, inhibiting cell viability and proliferation (IC50=4.72 μM) and promoting apoptosis by blocking the G0/G1 phase of the Hep3B cell cycle, inducing mitochondrial dysfunction and oxidative stress. In addition, PI3K/AKT-IN-4 inhibits hepatocellular carcinoma by inhibiting the PI3K-Akt signaling pathway and binding to PARP1 and CDK2 targets .
    PI3K/AKT-IN-4
  • HY-N2117
    Isoginkgetin
    10+ Cited Publications

    		 MMP Akt NF-κB Proteasome Apoptosis Autophagy Inflammation/Immunology Cancer
    Isoginkgetin is a pre-mRNA splicing inhibitor inhibitor. Isoginkgetin also inhibits activities of both Akt, NF-κB and MMP-9. Isoginkgetin inhibits the activity of the 20S proteasome, induces apoptosis and activates autophagy .
    Isoginkgetin
  • HY-124740
    ML00253764

    		Melanocortin Receptor Cancer
    ML00253764 is a selective melanocortin receptor 4 (MC4R) antagonist, can induce apoptosis by inhibiting ERK1/2 and Akt phosphorylation, and has anticancer activity .
    ML00253764

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: